Literature DB >> 17881000

Structural basis of the zinc inhibition of human tissue kallikrein 5.

Mekdes Debela1, Peter Goettig, Viktor Magdolen, Robert Huber, Norman M Schechter, Wolfram Bode.   

Abstract

Human kallikrein 5 (hK5) is a member of the tissue kallikrein family of serine peptidases. It has trypsin-like substrate specificity, is inhibited by metal ions, and is abundantly expressed in human skin, where it is believed to play a central role in desquamation. To further understand the interaction of hK5 with substrates and metal ions, active recombinant hK5 was crystallized in complex with the tripeptidyl aldehyde inhibitor leupeptin, and structures at 2.3 A resolution were obtained with and without Zn2+. While the overall structure and the specificity of S1 pocket for basic side-chains were similar to that of hK4, a closely related family member, both differed in their interaction with Zn2+. Unlike hK4, the 75-loop of hK5 is not structured to bind a Zn2+. Instead, Zn2+ binds adjacent to the active site, becoming coordinated by the imidazole rings of His99 and His96 not present in hK4. This zinc binding is accompanied by a large shift in the backbone conformation of the 99-loop and by large movements of both His side-chains. Modeling studies show that in the absence of bound leupeptin, Zn2+ is likely further coordinated by the imidazolyl side-chain of the catalytic His57 which can, similar to equivalent His57 imidazole groups in the related rat kallikrein proteinase tonin and in an engineered metal-binding rat trypsin, rotate out of its triad position to provide the third co-ordination site of the bound Zn2+, rendering Zn2+-bound hK5 inactive. In solution, this mode of binding likely occurs in the presence of free and substrate saturated hK5, as kinetic analyses of Zn2+ inhibition indicate a non-competitive mechanism. Supporting the His57 re-orientation, Zn2+ does not fully inhibit hK5 hydrolysis of tripeptidyl substrates containing a P2-His residue. The P2 and His57 imidazole groups would lie next to each other in the enzyme-substrate complex, indicating that incomplete inhibition is due to competition between both imidazole groups for Zn2+. The His96-99-57 triad is thus suggested to be responsible for the Zn2+-mediated inhibition of hK5 catalysis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17881000     DOI: 10.1016/j.jmb.2007.08.042

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  18 in total

1.  Computational investigation of the histidine ammonia-lyase reaction: a modified loop conformation and the role of the zinc(II) ion.

Authors:  Amalia-Laura Seff; Sarolta Pilbák; Ioan Silaghi-Dumitrescu; László Poppe
Journal:  J Mol Model       Date:  2010-10-05       Impact factor: 1.810

Review 2.  Kallikreins - The melting pot of activity and function.

Authors:  Magdalena Kalinska; Ulf Meyer-Hoffert; Tomasz Kantyka; Jan Potempa
Journal:  Biochimie       Date:  2015-09-25       Impact factor: 4.079

Review 3.  Involvement of corneodesmosome degradation and lamellar granule transportation in the desquamation process.

Authors:  Akemi Ishida-Yamamoto; Mari Kishibe
Journal:  Med Mol Morphol       Date:  2011-03-23       Impact factor: 2.309

Review 4.  Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Authors:  Ioannis Prassas; Azza Eissa; Gennadiy Poda; Eleftherios P Diamandis
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

5.  A Combined N-terminomics and Shotgun Proteomics Approach to Investigate the Responses of Human Cells to Rapamycin and Zinc at the Mitochondrial Level.

Authors:  Joanna Bons; Charlotte Macron; Catherine Aude-Garcia; Sebastian Alvaro Vaca-Jacome; Magali Rompais; Sarah Cianférani; Christine Carapito; Thierry Rabilloud
Journal:  Mol Cell Proteomics       Date:  2019-03-15       Impact factor: 5.911

6.  Isomannide-based peptidomimetics as inhibitors for human tissue kallikreins 5 and 7.

Authors:  Jocelia P C Oliveira; Renato F Freitas; Leandro Silva de Melo; Thalita G Barros; Jorge A N Santos; Maria A Juliano; Sérgio Pinheiro; Michael Blaber; Luiz Juliano; Estela M F Muri; Luciano Puzer
Journal:  ACS Med Chem Lett       Date:  2013-12-06       Impact factor: 4.345

7.  Chymotryptic specificity determinants in the 1.0 A structure of the zinc-inhibited human tissue kallikrein 7.

Authors:  Mekdes Debela; Petra Hess; Viktor Magdolen; Norman M Schechter; Thomas Steiner; Robert Huber; Wolfram Bode; Peter Goettig
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-01       Impact factor: 11.205

8.  Evolutionary history of tissue kallikreins.

Authors:  Athanasia Pavlopoulou; Georgios Pampalakis; Ioannis Michalopoulos; Georgia Sotiropoulou
Journal:  PLoS One       Date:  2010-11-01       Impact factor: 3.240

Review 9.  Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).

Authors:  Peter Goettig; Viktor Magdolen; Hans Brandstetter
Journal:  Biochimie       Date:  2010-07-06       Impact factor: 4.079

10.  Structural studies of complexes of kallikrein 4 with wild-type and mutated forms of the Kunitz-type inhibitor BbKI.

Authors:  Mi Li; Jaroslav Srp; Michael Mareš; Alexander Wlodawer; Alla Gustchina
Journal:  Acta Crystallogr D Struct Biol       Date:  2021-07-29       Impact factor: 5.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.